Lexitas https://validator.w3.org/feed/docs/rss2.html For Sponsors Home Navigating Ophthalmology: A Strategic Guide for Biotech Companies Entering the Space Webinar: Cell & Gene Therapy in Ophthalmology Expanding horizons: Why ophthalmology practices should consider embracing clinical trials Our Team The Importance of QC within a Reading Center Achieving Repeatability in Staining with a Modified NEI Scale Best Practices for Anterior Segment Ophthalmology Trials with Dr. Joseph Tauber A Vision for Growth Resources Advancing Corneal Staining Assessment with the Lexitas mCFS Scale 49th Macula Society Annual Meeting Investing in Vision: CRO Insights for Ophthalmic Innovators Considerations for Clinical Trial Sites Building Momentum: Strengthening Patient Retention in Clinical Trials 5 steps to secure funding for ophthalmic product development Navigating the maze: Establishing novel endpoints for IRD trials FDA Guidance: What it Means for AMD Clinical Trials The evolving landscape of ophthalmic clinical trials The Future Of Decentralized Clinical Trials In Ophthalmology Exciting happenings in retina research and care Finding Quality Clinical Research Sites The State of the Ophthalmology Funding Landscape David Tanzer, MD, CMO of Lexitas reflects on Retina World Congress Lexitas Monitors – Focused on Details and the Big Picture How Diversity, Equity and Inclusion in Clinical Trials Leads to Better Health Outcomes The Hidden Value of Onsite Monitoring Choosing a CRO – Avoiding the Trap of Commoditization What The Best Ophthalmology Sponsors Do Differently? All Under One Roof Our Plans to Help Bring More Ophthalmic Treatments to Patients Operationalizing an Ophthalmology Protocol One Size Fits None – Internal Focus at the Expense of Customer Relationships Terms of Use Advisory Board Reading Center Privacy Policy Five Key Considerations When Selecting an Ophthalmology CRO Inside Look: Patient Retention in Ophthalmic Clinical Trials Speeding Ophthalmic Trial Execution with an In-House Reading Center Inside Look: Lexitas’ Best Corrected Visual Acuity Certification Program Lexitas CEO Jeanne Hecht On Trends And Challenges In Ophthalmology Clinical Trials J.P. Morgan Takeaways with Jeanne Hecht Lanita Scott, M.D. – Maximizing the Likelihood of Success for Your Ophthalmology Clinical Trials Inside Look: Enrollment Rates in Ophthalmic Clinical Trials Lexitas Pharma Services Welcomes Dr. David Tanzer as Chief Medical Officer About Why Expertise in Ophthalmic Clinical Trials Matters for Medical and Protocol Writing  Contact